Capricor Therapeutics (CAPR) Misses Q1 EPS by 7c

Capricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of ($0.59), $0.07 worse than the analyst estimate of ($0.52).

Guidance

Financial Outlook: The Company believes that, based on the current operating plan and financial resources, its available cash, cash equivalents and marketable securities will be sufficient to cover anticipated expenses and capital requirements through Q4 2027. This outlook excludes any potential revenue from product sales, the potential monetization of a PRV, if received, or other non-operating sources of capital.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• KeyCorp (KEY) files for 158.72M share offering by selling stockholders
• ZenaTech raises Plurilock Security stake to 12% with new share purchase